In addition to addressing the humanitarian toll that Hurricane Maria has taken on the residents of Puerto Rico, an additional, long-term challenge in coping with the storm’s aftermath is the potential for drug shortages.
In addition to addressing the humanitarian toll that Hurricane Maria has taken on the residents of Puerto Rico, an additional, long-term challenge in coping with the storm’s aftermath is the potential for drug shortages.
According to a 2016 report, half of the world’s leading pharmaceutical companies operate in Puerto Rico, and 13 of the 20 top-selling drugs are manufactured there. With 80 FDA-approved manufacturing facilities, the island supplies critical medicines and devices, both to the rest of the United States and to 86 other countries.
Among the crucial products manufactured in Puerto Rico are Amgen’s pegfilgrastim (Neulasta) and etanercept (Enbrel), as well as AbbVie’s adalimumab (Humira). As no biosimilars are yet available for these treatments in the United States marketplace, patients have no alternatives to these branded products.
Also affected is methotrexate, a drug frequently used in the treatment of inflammatory conditions as well as some cancers. Methotrexate has been subject to previous shortages, and The New York Times reports that FDA officials are especially concerned about the supply of this product, which Mylan manufactures in Puerto Rico. The agency is reportedly maintaining a list of approximately 40 drugs about which it has supply concerns, 13 of which are only manufactured in Puerto Rico.
FDA Commissioner, Scott Gottlieb, MD, said in a statement this week that the agency is “working around the clock” to address potential “catastrophic” drug shortages resulting from the hurricane’s impacts on manufacturing facilities on the island. Gottlieb said that the agency worked closely with drug and device firms, during and after the storm, to determine the level of damage that facilities had sustained, and to assess whether facilities could continue to run on generator power.
Gottlieb highlighted the fact that the work to rebuild the pharmaceutical industry’s presence in Puerto Rico was not limited to addressing the short-term issue of drug shortages: “We need to ensure access to these critical treatments for the Americans who need them, but also recognize the important role that the medical product industry plays in helping Puerto Rico sustain its economy and help in its recovery,” he said. “The pharmaceutical industry in Puerto Rico is responsible for nearly 90,000 jobs, and the island will need them to recover and rebuild.”
While fears about an interrupted drug supply occupy many stakeholders, patients needing treatment in Puerto Rico’s hospitals have an even more acute set of concerns this week: NPR reports that approximately 75% of hospitals on the island are still relying on emergency generators for power, and temperatures in some hospitals had exceeded 108 degrees Fahrenheit. In hospitals that have experienced periods of power loss, some patients have had to be relocated into other, already crowded facilities, where patients face long waits for emergency care.
Biosimilar Policy Roundup—September 2024
October 1st 2024In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.